Company / Free Cash Flow
ANAPTYSBIO, INC Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$19.6M
FY2025
5-year range
-$135.7M / $19.6M
FY2021-FY2025
Trend
+114.5%
vs FY2024
Sector context
#63 of 194
Health Care
What the data says
At $20M, ANAPTYSBIO, INC's free cash flow ranks #63 of 194 in the Health Care sector. Free Cash Flow returned to growth in FY2025 after 2 years of decline, reaching $20M.
Based on SEC 10-K filings.
$20M in FY2025.
Improved from -$122M to $20M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#63 of 194 in Health CareTop 32% of 194This company $19.6M Sector average $470.6M
▼
-95.8% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 114.5% year-over-year.
- Ranks #63 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.6M | +114.5% |
| FY2024 | -$135.7M | -11.6% |
| FY2023 | -$121.6M | -725.8% |
| FY2022 | -$14.7M | +79.1% |
| FY2021 | -$70.3M | -41.9% |
| FY2020 | -$49.6M | -151.3% |
| FY2019 | -$19.7M | +60.2% |
| FY2018 | -$49.6M | -399.1% |
| FY2017 | -$9.9M | -9.4% |
| FY2016 | -$9.1M | +8.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026